Esperion Therapeutics, Inc.
Here’s whether Esperion Therapeutics, Inc. (ESPR) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.56% over 10 days); RSI 62 — healthy momentum range; strong 1-year return of +162.5%; 3-month momentum positive (+17.1%). Concerns: declining volume on rally — weak conviction (0.67x 30d avg). Currently 24.6% off its 52-week high. Score: +6/7.
ESPR is in a confirmed uptrend, trading above both its 50-day ($2.72) and 200-day ($3.00) moving averages. An RSI of 62.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +162.5% compares to +22.9% for SPY (beat the market by 139.6%). The current 24.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.